C

CeriBell Inc
NASDAQ:CBLL

Watchlist Manager
CeriBell Inc
NASDAQ:CBLL
Watchlist
Price: 15.99 USD 1.2%
Market Cap: 577.9m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one CBLL stock under the Base Case scenario is hidden USD. Compared to the current market price of 15.99 USD, CeriBell Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

CBLL Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

8.8
P/S
P/S
Price to Sales
8.8
vs History
81
vs Industry
Median 3Y
10.3
Median 5Y
10.3
Industry
2.3
Forward
6.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-16.7
Median 5Y
-16.7
Industry
22
Forward
-10
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-23.5
Median 5Y
-23.5
Industry
14.3
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-26.9
Median 5Y
-26.9
Industry
20
More Details
3.2
P/B
P/B
Price to Book Value
3.2
vs History
81
vs Industry
Median 3Y
3.7
Median 5Y
3.7
Industry
2.2
More Details
6.2
EV/S
EV/S
Enterprise Value to Sales
6.2
vs History
81
vs Industry
Median 3Y
7.8
Median 5Y
7.8
Industry
2.4
Forward
4.6
More Details
7.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
7.1
vs History
81
vs Industry
Median 3Y
9
Median 5Y
9
Industry
5
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-13.4
Median 5Y
-13.4
Industry
11.6
Forward
-7.4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-12.9
Median 5Y
-12.9
Industry
15.9
Forward
-7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-18.6
Median 5Y
-18.6
Industry
14.3
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-17.7
Median 5Y
-17.7
Industry
18
More Details
13.7
EV/IC
EV/IC
Enterprise Value to IC
13.7
vs History
81
vs Industry
Median 3Y
17.4
Median 5Y
17.4
Industry
1.8
More Details

Multiples Across Competitors

CBLL Competitors Multiples
CeriBell Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
CeriBell Inc
NASDAQ:CBLL
567.2m USD 8.8 -14.2 -10.6 -10.2
US
Abbott Laboratories
NYSE:ABT
212.1B USD 5 15.6 20.4 29.3
US
Intuitive Surgical Inc
NASDAQ:ISRG
183.9B USD 21.2 74.4 59.8 72.7
US
Boston Scientific Corp
NYSE:BSX
153.6B USD 8.7 75.5 35.6 49.6
US
Stryker Corp
NYSE:SYK
148.7B USD 6.4 52 25.7 31
IE
Medtronic PLC
NYSE:MDT
114.2B USD 3.4 24.5 13.7 19.5
DE
Siemens Healthineers AG
XETRA:SHL
51.9B EUR 2.2 24.9 14 19.4
US
Becton Dickinson and Co
NYSE:BDX
51.3B USD 2.5 33.9 13.4 25.1
US
Edwards Lifesciences Corp
NYSE:EW
44.8B USD 8.1 10.7 24.5 27
US
IDEXX Laboratories Inc
NASDAQ:IDXX
41.8B USD 10.6 46.8 33.1 37
US
Resmed Inc
NYSE:RMD
37.4B USD 7.4 28.5 20.3 23
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
C
CeriBell Inc
NASDAQ:CBLL
Average EV/EBITDA: 26.1
Negative Multiple: -10.6 		N/A N/A
US
Abbott Laboratories
NYSE:ABT
20.4
13%
1.6
US
Intuitive Surgical Inc
NASDAQ:ISRG
59.8
24%
2.5
US
Boston Scientific Corp
NYSE:BSX
35.6
21%
1.7
US
Stryker Corp
NYSE:SYK
25.7
12%
2.1
IE
Medtronic PLC
NYSE:MDT
13.7
7%
2
DE
Siemens Healthineers AG
XETRA:SHL
14
14%
1
US
Becton Dickinson and Co
NYSE:BDX
13.4
11%
1.2
US
Edwards Lifesciences Corp
NYSE:EW
24.5
12%
2
US
IDEXX Laboratories Inc
NASDAQ:IDXX
33.1
12%
2.8
US
Resmed Inc
NYSE:RMD
20.3
12%
1.7
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
C
CeriBell Inc
NASDAQ:CBLL
Average EV/EBIT: 33.4
Negative Multiple: -10.2 		N/A N/A
US
Abbott Laboratories
NYSE:ABT
29.3
22%
1.3
US
Intuitive Surgical Inc
NASDAQ:ISRG
72.7
26%
2.8
US
Boston Scientific Corp
NYSE:BSX
49.6
31%
1.6
US
Stryker Corp
NYSE:SYK
31
16%
1.9
IE
Medtronic PLC
NYSE:MDT
19.5
15%
1.3
DE
Siemens Healthineers AG
XETRA:SHL
19.4
19%
1
US
Becton Dickinson and Co
NYSE:BDX
25.1
28%
0.9
US
Edwards Lifesciences Corp
NYSE:EW
27
12%
2.3
US
IDEXX Laboratories Inc
NASDAQ:IDXX
37
12%
3.1
US
Resmed Inc
NYSE:RMD
23
14%
1.6

See Also

Summary
CBLL intrinsic value, competitors valuation, and company profile.
DCF Valuation
CBLL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CBLL stock valuation using valuation multiples.
Wall Street Estimates
CBLL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CBLL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 268,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.